About

Biological products include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins.
Biologics manufacturing is a complex procedure, and it takes time and effort.

While classical therapeutic small molecules are made by well-known organic or chemical synthesis with few critical steps, biologics (and biosimilars) are produced by living cells in a very complex process with several critical phases.

Moreover, the biological molecule itself is complex. Unlike small molecular drugs, whose structure is homogeneous and well characterized, biologics (and biosimilars) are less easily characterized because of their intrinsic heterogeneous nature (several physiological isoforms).
Precisely because biologics are produced in living cells, it is almost impossible to guarantee that each batch is identical to the previous one. In any case, manufacturers are required to have as much control over the process as possible to identify and manage unexpected variations which may affect product quality, efficacy, and safety.

Taking into account the specific nature of biologics, based on regulatory guidance and case studies, this course aims to explain the regulatory considerations for biologics and biosimilars manufacturing to obtain clinical trials and marketing authorizations in Europe. Among the vast world of biologics, we will focus on monoclonal antibodies, vaccines, and insulins.

  • Introduction and history of biologics and biosimilars
  • Current regulatory landscape in Europe regarding biologics manufacturing and analytical method
  • An overview of the challenges related to biologics development, manufacturing and characterization: insights into reconciling regulatory requirements and technical difficulties in the production process and analytical methods
  • Common regulatory findings: case studies discussion to avoid non-conformities
  • EU vs US regulatory differences and how these can impact production and control
  • What do Authorities expect in case of manufacturing variations? Activities and documentation to be performed and presented by the Production, Quality Control, Quality Assurance and Chemistry, Manufacturing and Control (CMC) departments
  • Definition of biosimilarity and biocomparability: product-specific biosimilar guidelines to keep in mind
  • Characterization of biosimilars with respect to the originator molecules: the great initial analytical effort to get a smoother clinical commitment
  • An overview of the registration pathway for biosimilars aimed at non regulatory personnel

Personnel working in and with CMC, manufacturing/analytical method development and validation areas, who are interested in knowing regulatory requirements for biologics and discussing how to meet them.

Participant experience
Ideally 1-2 years experience in biologics manufacturing and characterization, in order to enrich the discussion and exchange during our training.

The workshop is intended to be a ‘two-way’ learning and discussion experience; questions and subsequent discussion are welcome at any time during the workshop.
The presentation will be followed by questions and answers throughout the training.

Lecturers
Fernanda Manhães
Info

Fernanda Manhães

PharmD, MSc, Independent Regulatory Affairs Consultant – REGX Solutions

Fernanda has a PharmD degree and a Master in Health Economics and Pharmacoeconomics, with more than 10 years of experience in Regulatory Affairs having assisted pharmaceutical companies in all stages of growth, from start-ups to established multinationals needing assistance with the global regulatory strategy to filings in Europe, US and Brazil. Her experience ranges from clinical trials to marketing authorizations and post-authorizations including chemicals, biologics, and medical devices/combination products.

Online Training – 2 modules

Module 1 | 24 June 2024 from 2:00 pm to 6:00 pm CEST
Module 2 | 26 June 2024 from 2:00 pm to 6:00 pm CEST

After the registration, you will receive all details about the connection.

The course will proceed with a minimum number of participants. Should this number not be reached the registered participants will be notified one week prior to the commencement of the course.

Early Bird: € 905,00* (until 03 June 2024)

Ordinary: € 1095,00*

Freelance – Academy – Public Administration**: € 590,00*

* for Italian companies: +22% VAT

** Early Bird discount not applicable to Freelance – Academy – Public Administration fee

The fee includes: tuition, organizational office assistance, teaching materials and attendance certificate that will be sent after the training via e-mail.

Register
Early Bird
Available until 03/06/2024
€905,00
Ordinary
Available until 23/06/2024
€1.095,00
Freelance – Individual – Academy – Public Administration
Available until 23/06/2024
€590,00
Clear
Roberta Alberti
Roberta Alberti
Events & Training Manager
Printable Version
At the end of the training, you will be able to
Risultato atteso
Know which regulatory guidance will be the basis for your work during biologics development, manufacturing and control
Risultato atteso
Identify the challenges in biologics manufacturing once working with both EU and US markets
Risultato atteso
Be better prepared for an audit or Regulatory Inspection
<p><span>Online interactive training on Zoom platform. </span></p> <p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>

Online interactive training on Zoom platform. 

LS Academy will provide the access link to the virtual platform a few days before the training.

<p><span>Online interactive training on Zoom platform. </span></p> <p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>
View all editions
Biologics and biosimilars manufacturing